KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Gross Margin (2021 - 2025)

Novavax (NVAX) has 10 years of Gross Margin data on record, last reported at 84.98% in Q4 2025.

  • For Q4 2025, Gross Margin rose 2650.0% year-over-year to 84.98%; the TTM value through Dec 2025 reached 93.1%, up 2282.0%, while the annual FY2025 figure was 93.5%, 2322.0% up from the prior year.
  • Gross Margin reached 84.98% in Q4 2025 per NVAX's latest filing, up from 69.48% in the prior quarter.
  • Across five years, Gross Margin topped out at 100.0% in Q1 2021 and bottomed at 45.8% in Q2 2022.
  • Average Gross Margin over 5 years is 66.84%, with a median of 77.23% recorded in 2025.
  • Peak YoY movement for Gross Margin: plummeted -14580bps in 2022, then surged 13266bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 100.0% in 2021, then crashed by -51bps to 49.14% in 2022, then decreased by -5bps to 46.81% in 2023, then rose by 25bps to 58.48% in 2024, then skyrocketed by 45bps to 84.98% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 84.98% in Q4 2025, 69.48% in Q3 2025, and 91.24% in Q2 2025.